The use of genotyping in Streptococcus pneumoniae of serotype 19A to estimate the risk of vaccine replacement.
Project goals
Respiratory tract infections are the leading causes of childhood mortality in the third world. Pneumococcal pneumonia is among the most serious respiratory tract infections and the pneumococcus is also the leading cause of meningitis, pneumonia and acuteotitis media in the developed countries. Acute otitis media is the most common indication for antibiotic use in Europe, which creates great selective pressure for resistant pneumococci. Interventions to reduce the burden of pneumococcal disease are important. Vaccination with a new protein conjugated pneumococcal vaccine has proved to reduce the burden of pneumococcal disease significantly in the United States and several European countries. Unfortunately, the vaccine does not cover all pneumococci andsome clones/families have increased markedly following the introduction of the new vaccine. Understanding the epidemiology and changes following interventions requires knowledge about clones circulating in the communities before the introduction of t
Keywords
Streptococcus pneumoniaeantibiotikarezistenceserotyppiluskonjugovaná vakcína
Public support
Provider
Ministry of Education, Youth and Sports
Programme
EEA/Norwegian Financial Mechanism
Call for proposals
—
Main participants
—
Contest type
RP - Co-financing of EC programme
Contract ID
22557/2010-611
Alternative language
Project name in Czech
The use of genotyping in Streptococcus pneumoniae of serotype 19A to estimate the risk of vaccine replacement.
Annotation in Czech
Respiratory tract infections are the leading causes of childhood mortality in the third world. Pneumococcal pneumonia is among the most serious respiratory tract infections and the pneumococcus is also the leading cause of meningitis, pneumonia and acuteotitis media in the developed countries. Acute otitis media is the most common indication for antibiotic use in Europe, which creates great selective pressure for resistant pneumococci. Interventions to reduce the burden of pneumococcal disease are important. Vaccination with a new protein conjugated pneumococcal vaccine has proved to reduce the burden of pneumococcal disease significantly in the United States and several European countries. Unfortunately, the vaccine does not cover all pneumococci andsome clones/families have increased markedly following the introduction of the new vaccine. Understanding the epidemiology and changes following interventions requires knowledge about clones circulating in the communities before the introduction of t
Scientific branches
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider
Solution timeline
Realization period - beginning
Apr 1, 2010
Realization period - end
Dec 31, 2010
Project status
U - Finished project
Latest support payment
Nov 9, 2010
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP11-MSM-7F-U/01:1
Data delivery date
Jun 30, 2011
Finance
Total approved costs
117 thou. CZK
Public financial support
117 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Recognised costs
117 CZK thou.
Public support
117 CZK thou.
0%
Provider
Ministry of Education, Youth and Sports
CEP
EE - Microbiology, virology
Solution period
01. 04. 2010 - 31. 12. 2010